Cytokine Dysregulation in Acute Graft-versus-Host Disease

References

• Storb, R. (1995). Prevention of graft-versus-host disease after bone marrow transplantation, Transplant. Proceed., 27, 2653–2656.
   PubMed Web of Science ®Google Scholar
• Ringden, O. and Deeg, H. J. (1997). Clinical spectrum of graft-versus-host disease. In Graft-vs-host disease, 2nd edition, Edited by Ferrara, J. L. M., Deeg, H. J. and Burakoff, S. J. pp. 525–559, New York, Marcel Dekker, Inc.
   Google Scholar
• Hakim, F. T. and Mackall, C. L. (1997). The immune system: effector and target of graft-versus-host disease. In: Graft-vs-host disease, Edited by Ferrara, J. L. M., Deeg, H. J. and Burakoff, S. J. pp. 257–289, New York, Marcel Dekker, Inc.
   Google Scholar
• Martin, P. J. and Keman, N. A. (1997). T-cell depletion for GVHD prevention in humans. In: Graft-vs-Host Disease, 2nd Edition., Edited by Ferrara, J. L. M., Deeg, H. J. and Burakoff, S. J. pp. 615–638, New York, Marcel Dekker, Inc.
   Google Scholar
• Holler, E. and Ferrara, J. L. M. (1997). Antagonists of inflammatory cytokines: prophylactic and therapeutic applications. In: Graft-vs-host disease, Edited by Ferrara, J. L. M., Deeg, H. J. and Burakoff, S. J. pp. 667–692, New York, Marcel Dekker, Inc.
   Google Scholar
• Deeg, H. J. (1994). Prophylaxis and treatment of acute graft-versus-host disease: current state, implications of new immunopharmacologic compounds and future strategies to prevent and treat acute GVHD in high-risk patients, Bone Marrow Transplant., 14, S56–60.
   PubMed Web of Science ®Google Scholar
• Xun, C. Q., Thompson, J. S., Jennings, C. D., Brown, S. A. and Widmer, M. B. (1994). Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice, Blood, 83, 2360–2367.
   PubMed Web of Science ®Google Scholar
• Remberger, M., Ringden, O. and Markling, L. (1995). TNFα levels are increased during bone marrow transplantation conditioning in patients who develop acute GVHD, Bone Marrow Transplant., 15, 99–104.
   PubMed Web of Science ®Google Scholar
• Eissner, G., Kohlhuber, F., Grell, M., Ueffing, M., Scheurich, P., Hieke, A., Multhoff, G., Bornkamm, G. W. and Holler, E. (1995). Critical involvement of transmembrane tumor necrosis factor-alpha in endothelial programmed cell death mediated by ionizing radiation and bacterial endotoxin, Blood, 86, 4184–4193.
   PubMed Web of Science ®Google Scholar
• Behrends, U., Peter, R. U., Hintermeier-Knabe, R., Eissner, G., Holler, E., Bomkamm, G. W., Caughman, S. W. and Degitz, K. (1994). Ionizing radiation induces human intercellular adhesion molecule-1 in vitro. J. Investri. Dermatol., 103, 726–730.
   PubMed Web of Science ®Google Scholar
• Lichtman, A., Krenger, W. and Ferrara, J. L. M. (1997). Cytokine networks. In: Graft-Versus-Host Disease, 2nd Edition., Edited by Ferrara, J. L. M., Deeg, H. J. and Burakoff, S. J. pp. 179–218. New York. Marcel Dekker, Inc.
   Google Scholar
• Hill, G. R., Crawford, J. M., Cooke, K. J., Brinson, Y. S., Pan, L. and Ferrara, J. L. M. (1997). Total body irradiation effects on acute graft versus host disease. The role of gastrointestinal damage and inflammatory cytokines. Blood, 90, 3204–3213.
   PubMed Web of Science ®Google Scholar
• Tough, D. F., Sun, S. and Sprent, J. (1997). T cell stimulation in vivo by lipopolysaccharide (LPS). J. Exp. Med., 185, 2089–2094.
   PubMed Web of Science ®Google Scholar
• Vella, A. T., Mitchell, T., Groth, B., Linsley, P. S., Green, J. M., Thompson, C. B., Kappler, J. W. and Marrack, P. (1997). CD28 engagement and proinflammatory cytokines contribute to T cell expansion and long term survival in vivo. J. Immunol., 158, 4714–4720.
   PubMed Web of Science ®Google Scholar
• Holler, E., Kolb, H. J., Moller, A., Kempeni, J., Lisenfeld, S., Pechumer, H., Lehmacher, W., Ruckdeschel, G., Gleixner, B., Riedner, C., Ledderose, G., Brehm, G., Mittermuller, J. and Wilmanns, W. (1990). Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood, 75, 1011–1016.
   PubMed Web of Science ®Google Scholar
• Holler, E., Kolb, H. J., Mittermueller, J., Kaul, M., Ledderose, G., Duell, T., Seeber, B., Schleuning, M., Hintermeier-Knabe, R., Ertl, B., Kempeni, J. and Wilmanns, W. (1995). Modulation of acute graft-versus-host disease after allogeneic bone marrow transplantation by tumor necrosis factor α (TNFα) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNFα (MAK 195F). Blood, 86, 890–899.
   PubMed Web of Science ®Google Scholar
• Komgold, R. and Sprent, J. (1990). T cell subsets in graft-vs-host disease. In: Graft-vs-Host Disease: Immunology, Pathophysiology, and Treatment, Edited by Burakoff, S. J., Deeg, H., Ferrara, J. and Atkinson, K. pp. 31–50. New York Marcel Dekker, Inc.
   Google Scholar
• Korngold, R. and Sprent, J. (1982). Features of T cells causing H-2 restricted lethal graft-vs-host disease across minor histocompatibility barriers. J. Exp. Med., 155, 872–873.
   PubMed Web of Science ®Google Scholar
• Mosmann, T. R., Cherwinski, H., Bond, M. W., Giedlin, M. A. and Coffman, R. L. (1986). Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol., 136, 2348–2357.
   PubMed Web of Science ®Google Scholar
• Seder, R. A. (1995). The functional role of CD8+ T helper type 2 cells. J. Exp. Med., 181, 5–7.
   PubMed Web of Science ®Google Scholar
• Nestel, F. P., Price, K. S., Seemayer, T. A. and Lapp, W. S. (1992). Macrophage priming and lipopolysaccharidetriggered release of tumor necrosis factor alpha during graft-versus-host disease. J. Exp. Med., 175, 405–413.
   PubMed Web of Science ®Google Scholar
• Via, C. S. and Finkelman, F. D. (1993). Critical role of interleukin-2 in the development of acute graft-versus-host disease. Int. Immunol., 5, 565–572.
   PubMed Web of Science ®Google Scholar
• Theobald, M., Nierle, T., Bunjes, D., Arnold, R. and Heimpel, H. (1992). Host-specific interleukin-2-secreting donor T-cell precursors as predictors of acute graft-versus-host disease in bone marrow transplantation between HLA-identical siblings. N. Engl. J. Med., 327, 1613–1617.
   PubMed Web of Science ®Google Scholar
• Schwarer, A. P., Jiang, Y. Z., Brookes, P. A., Barrett, A. J., Batchelor, J. R., Goldman, J. M. and Lechler, R. I. (1993). Frequency of anti-recipient alloreactive helper T-cell precursors in donor blood and graft-versus-host disease after HLA-identical sibling bone-marrow transplantation. Lancet, 341, 203–205.
   PubMed Web of Science ®Google Scholar
• Gribben, J. G., Guinan, E. C., Boussiotis, V. A., Ke, X. Y., Linsley, L., Sieff, C., Gray, G. S., Freeman, G. J. and Nadler, L. M. (1996). Complete blockade of B7 familymediated costimulation is necessary to induce human alloantigen-specific anergy: a method to ameliorate graft-versus-host disease and extend the donor pool. Blood, 87, 4887–4893.
   PubMed Web of Science ®Google Scholar
• Miyamoto, T., Akashi, K., Hayashi, S., Gondo, H., Murakawa, M., Tanimoto, K., Harada, M. and Niho, Y. (1996). Serum concentration of the soluble interleukin-2 receptor for monitoring acute graft-versus-host disease. Bone Marrow Transplant., 17, 185–190.
   PubMed Web of Science ®Google Scholar
• Ringden, O. (1986). Cyclosporine in allogeneic bone marrow transplantation. Transplantation, 42, 445–452.
   PubMed Web of Science ®Google Scholar
• Anasetti, C., Hansen, J. A., Waldmann, T. A., Applebaum, F. R., Davis, J., Deeg, H. J., Doney, K., Martin, P. J., Nash, R., Storb, R., Sullivan, K. M., Witherspoon, R. P., Binger, M., Chizzonite, R., Hakimi, J., Mould, D., Satoh, H. and Light, S. E. (1994). Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. Blood, 84, 1320–1327.
   PubMed Web of Science ®Google Scholar
• Cahn, J. Y., Bordigoni, P., Tiberghien, P., Milpied, N., Brion, A., Widjenes, J., Lioure, B., Michel, G., Burdach, S., Kolb, H., Link, H., Vernant, J., Ifrah, N., Racadot, E., Herve, P. and Ehninger, G. (1995). Treatment of acute graft-versus-host disease with methylprednisolone and cyclosporine with or without an anti-interleukin-2 receptor monoclonal antibody. Transplantation, 60, 939–942.
   PubMed Web of Science ®Google Scholar
• Anasetti, C., Martin, P. J., Storb, R., Appelbaum, F. R., Beatty, P. G., Calori, E., Davis, J., Doney, K., Riechert, T., Stewart, P., Sullivan, K. M., Thomas, E. D., Witherspoon, R. P. and Hansen, J. A. (1991). Prophylaxis of graft-versus-host disease by administration of the murine anti-IL-2 receptor antibody 2A3. Bone Marrow Transplant., 7, 375–381.
   PubMed Web of Science ®Google Scholar
• Blaise, D., Marananinchi, D., Mawas, C., Stoppa, A. M., Him, M., Guyotat, D., Attal, M. and Reiffers, J. (1989) Prevention of acute graft-versus-host disease by monoclonal antibody to interleukin 2 receptor. Lancet, 1, 1333–1334.
   PubMed Web of Science ®Google Scholar
• Blaise, D., Olive, D., Michallet, M., Marit, G., Leblond, V. and Maraninchi, D. (1995). Impairment of leukaemia-free survival by addition of interleukin-2 receptor antibody to standard graft-versus-host prophylaxsis. Lancet, 345, 1144–66.
   PubMed Web of Science ®Google Scholar
• Belanger, C., Esperou-Bourdeau, H., Bordigoni, P., Jouet, J. P., Souillet, G., Milpied, N., Troussard, X., Kuentz, M., Herve, P., Reiffers, J., Demeocq, F., Dauriac, C., Blaise, D., Michallet, M., Friere, D., Freycon, F., Gratecos, N., Rio, B., Leblond, V., Ifrah, N., Attal, M., Bergerat, J. P., Vilmer, E., Pico, J., Raffoux, C., Caudrelier, P. and Gluckman, E. (1993). Use of an anti-interleukin-2 receptor monoclonal antibody for GVHD prophylaxis in unrelated donor BMT. Bone Marrow Transplant., 11, 293–297.
   PubMed Web of Science ®Google Scholar
• Massumoto, C., Benyunes, M. C. and Sale, G. (1996). Close simulation of acute graft-versus-host disease by interleukin-2 administered after autologous bone marrow transplantation for hematologic malignancies. Bone Marrow Transplant., 17, 351–356.
   PubMed Web of Science ®Google Scholar
• Weiss, L., Lubin, I., Factorowich, I., Lapidot, Z., Reich, S., Reisner, Y. and Slavin, S. (1994). Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell depleted allogeneic bone marrow transplantation in a murine model of B cell leukmia/lymphoma. Role of cell thereby and recombinant IL-2. J. Immunol., 153, 2562–2567.
   PubMed Web of Science ®Google Scholar
• Soiffer, R. J., Murray, C., Cochran, K., Cameron, C., Wang, E., Schow, P. W., Daley, J. F. and Ritz, J. (1992). Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depeleted bone marrow transplantation. Blood, 79, 517–526.
   PubMed Web of Science ®Google Scholar
• Robinson, N., Sanders, J. E., Benyunes, M. C., Beach, K., Lindgren, C., Thompson, J. A., Appelbaum, F. R. and Fefer, A. (1996). Phase I trial of interleukin-2 after unmodified HLA-matched sibling bone marrow transplantation for children with acute leukemia. Blood, 87, 1249–1254.
   PubMed Web of Science ®Google Scholar
• Sykes, M., Romick, M. L., Hoyles, K. A. and Sachs, D. H. (1990). In vivo administration of interleukin 2 plus T cell-depleted syngeneic marrow prevents graft-versus-host disease mortality and permits alloengraftment. J. Exp. Med., 171, 645–658.
   PubMed Web of Science ®Google Scholar
• Szebeni, J., Wang, M. G., Pearson, D. A., Szot, G. L. and Sykes, M. (1994). IL-2 inhibits early increases in serum gamma interferon levels associated with graft-versus-host disease. Transplantation., 58, 1385–1393.
   PubMed Web of Science ®Google Scholar
• Wang, M. G., Szebeni, J., Pearson, D. A., Szot, G. L. and Sykes, M. (1995). Inhibition of graft-versus-host disease by interleukin-2 treatment is associated with altered cytokine production by expanded graft-versus-host-reactive CD4+ helper cells. Transplantation, 60, 481–490.
   PubMed Web of Science ®Google Scholar
• Sykes, M., Abraham, V. S., Harty, M. W. and Pearson, D. A. (1993) IL-2 reduces graft versus-host disease and preserves a graft-versus-leukemia effect by selectively inhibiting CD4+ T cell activity. J. Immunol., 150, 197–205.
   PubMed Web of Science ®Google Scholar
• Sykes, M., Szot, G. L., Nguyen, P. L. and Pearson, D. A. (1995). Interleukin-12 inhibits murine graft-versus-host disease. Blood, 86, 2429–2438.
   PubMed Web of Science ®Google Scholar
• Troutt, A. B., Maraskovsky, E., Rogers, L. A., Pech, M. H. and Kelso, A. (1992). Quantitative analysis of lymphokine expression in vivo and in vitro. Immunol. Cell Biot., 70, 51–57.
   PubMed Web of Science ®Google Scholar
• Allen, R. D., Staley, T. A. and Sidman, C. L. (1993). Differential cytokine expression in acute and chronic murine graft-versus-host disease. Eur. J. Immunol., 23, 333–337.
   PubMed Web of Science ®Google Scholar
• Garside, P., Reid, S., Steel, M. and Mowat, A. M. (1994) Differential cytokine production associated with distinct phases of murine graft-versus-host reaction. Immunol., 82, 211–214.
   PubMed Web of Science ®Google Scholar
• Ferrara, J. L. M., Cooke, K. R., Pan, L. and Krenger, W. (1996). The immunopathophysiology of acute graft-versus-host disease. Stem Cells, 14, 473–489.
   PubMed Web of Science ®Google Scholar
• Mowat, A. (1989). Antibodies to IFN-gamma prevent immunological mediated intestinal damage in murine graft-versus-host reactions. Immunol., 68, 18–24.
   PubMed Web of Science ®Google Scholar
• Dickinson, A. M., Sviland, L., Dunn, J., Carey, P. and Proctor, S. J. (1991). Demonstration of direct involvement of cytokines in graft-versus-host reactions using an in vitro skin explant model. Bone Marrow Transplant., 7, 209–216.
   PubMed Web of Science ®Google Scholar
• Wall, D. A. and Sheehan, K. C. (1994). The role of tumor necrosis factor-alpha and interferon gamma in graft-versus-host disease and related immunodeficiency. Transplantation, 57, 273–279.
   PubMed Web of Science ®Google Scholar
• Huchet, R., Bruley-Rosset, M., Mathiot, C., Grandjon, D. and Halle-Pannenko, O. (1993). Involvement of IFN-gamma and transforming growth factor-beta in graft-vs-host reaction associated immunosuppression. J. Immunol., 150, 2517–2524.
   PubMed Web of Science ®Google Scholar
• Krenger, W., Falzarano, G., Delmonte, J., Snyder, K. M., Byon, J. C. H. and Ferrara, J. L. M. (1996). Interferon-γ suppresses T-cell proliferation to mitogen via the nitric oxide pathway during experimental acute graft-versus-host disease. Blood, 88, 1113–1121.
   PubMed Web of Science ®Google Scholar
• Rus, V., Svetic, A., Nguyen, P., Gause, W. C. and Via, C. S. (1995). Kinetics of Th1 and Th2 cytokine production during the early course of acute and chronic murine graft-versus-host disease. J. Immunol., 155, 2396–2406.
   PubMed Web of Science ®Google Scholar
• Brok, H. P. M., Heidt, P. J., van der Meide, P. H., Zurcher, C. and Vossen, J. M. (1993). Interferon-γ6459.
   Google Scholar
• Smith, S. R., Terminelli, C., Pennline, K., Kenworthy-Bott, L., Donkin, J. and Calzetta, A. (1995). Inhibitory effects of recombinant human interleukin 10 on disease manifestations in a P→F1 model of acute graft-versus-host disease. Transplantation., 59, 890–896.
   PubMed Web of Science ®Google Scholar
• Carayon, P., Bouaboula, M., Loubet, J. F., Bourrie, B., Petitpretre, G., Le Fur, G. and Casellas, P. (1995). The sigma ligand SR 31747 prevents the development of acute graft-versus-host disease in mice by bloclcing IFN-gamma and GM-CSF mRNA expression. Int. J. Immunopharmacol., 17, 753–761.
   PubMed Web of Science ®Google Scholar
• Krenger, W., Snyder, K. M., Byon, C. H., Falzarano, G. and Ferrara, J. L. M. (1995). Polarized type 2 alloreactive CD4+ and CD8+ donor T cells fail to induce experimental acute graft-versus-host disease. J. Immunol., 155, 585–593.
   PubMed Web of Science ®Google Scholar
• Fowler, D. H., Kurasawa, K., Husebekk, A., Cohen, P. A. and Gress, R. E. (1994). Cells of the Th2 cytokine phentope prevent LPS-induced lethality during murine graft-versus-host reaction. J. Immunol., 152, 1004–1011.
   PubMed Web of Science ®Google Scholar
• Imamura, M., Hashino, S., Kobayashi, H., Kubayashi, S., Hiroano, S., Minagawa, T., Tanaka, J., Fujii, Y., Kobayashi, M., Kasai, M., Sakurada, K. and Miyazaki, T. (1994). Serum cytokine levels in bone marrow transplantation: synergistic interaction of interleukin-6, interferon gamma, and tumor necrosis factor-alpha in graft-versus-host disease. Bone Marrow Transplant, 13, 745–751.
   PubMed Web of Science ®Google Scholar
• Niederwieser, D., Herold, M., Woloszczuk, W., Aulitsky, W., Meister, B., Tilg, H., Gastl, G., Bowden, R. and Huber, C. (1990). Endogenous IFN-gamma during human bone marrow transplantation. Transplantation, 50, 620–625.
   PubMed Web of Science ®Google Scholar
• Kennedy, M. J., Vogelsang, G. B., Jones, R. J., Farmer, E. R., Hess, A. D., Altomonte, V., Huelskamp, A. M. and Davidson, N. E. (1994). Phase I trial of interferon gamma to potentiate cyclosporine-induced graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. J. Clin. Oncol., 12, 249–257.
   PubMed Web of Science ®Google Scholar
• Dickinson, A. M., Sviland, L., Hamilton, P. J., Usher, P., Taylor, P., Jackson, G., Dunn, J. and Proctor, S. J. (1994). Cytokine involvement in predicting clinical graft-versus-host disease in allogenic bone marrow transplant recipients. Bone Marrow Transplant., 13, 65–70.
   PubMed Web of Science ®Google Scholar
• Tanaka, J., Imamura, M., Kasai, M., Kobayashi, S., Hashino, S., Kobayashi, H., Sakurada, K. and Miyazaki, T. (1994). Cytokine gene expression in the mixed lymphocyte culture in allogenic bone marrow transplants as a predictive method for transplantationrelated complications. Br. J. Haematol., 87, 415–418.
   PubMed Web of Science ®Google Scholar
• Roncarolo, M. G., Bigler, M., Ciuti, E., Martino, S. and Tovo, P. A. (1994). Immune responses by cord blood cells. Blood Cells, 20, 573–585.
   PubMedGoogle Scholar
• Kurtzberg, J., Laughlin, M. and Graham, M. L. (1996). Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N. Engl. J. Med., 335, 157–166.
   PubMed Web of Science ®Google Scholar
• Heinzel, F. P., Sadick, M. D., Holaday, B. J., Coffmann, R. L. and Locksley, R. M. (1989). Reciprocal expression of interferon-γ or interleukin-4 during the resolution or progression of murine leishmaniasis. J. Exp. Med., 169, 59–72.
   PubMed Web of Science ®Google Scholar
• Romagnani, S. (1994). Lymphokine production by human T cells in disease states. Annual Rev. Immunol., 12, 227–57.
   PubMed Web of Science ®Google Scholar
• Sher, A., Gazzinelli, R. T., Oswals, I. P., Clerici, M., Kullberg, M., Pearce, E. J., Berzowsky, J. A., Mosmann, T. R., James, S. L. and Morse, H. C. (1992). Role of T cell-derived cytokines in the downregulation of immune responses in parasitic and retroviral infection. Immunol. Rev., 127, 183–204.
   PubMed Web of Science ®Google Scholar
• Doutrelepont, J. M., Moser, M., Leo, O., Abramowicz, D., Vanderhaegen, M. L., Urbain, J. and Goldman, M. (1991). HyperIgE in stimulatory graft-versus-host disease: role of Interleukin-4. Clin. Exp. Immunol., 83, 133–136.
   PubMed Web of Science ®Google Scholar
• DeWit, D., Van Mechelen, M., Zanin, C., Doutrelepont, J.-M., Velu, T., Gerard, C., Abramowicz, D., Scheerlinck, J.-P., De Baetselier, P., Urbain, J., Leo, O., Goldman, M. and Moser, M. (1993). Preferential activation of Th2 cells in chronic graft-versus-host disease. J. Immunol., 150, 361–366.
   PubMed Web of Science ®Google Scholar
• Garlisi, C. G., Pennline, K. J., Smith, S. R., Siegel, M. I. and Umland, S. P. (1993). Cytokine gene expression in mice undergoing chronic graft-versus-host disease. Mol. Immunol., 30, 669–677.
   PubMed Web of Science ®Google Scholar
• Via, C. S., Rus, V., Gately, M. K. and Finkelman, F. D. (1994) IL-12 stimulates the development of acute graft-versus-host disease in mice that would normally develop chronic, autoimmune graft-versus-host disease. J. Immunol., 153, 4040–4047.
   PubMed Web of Science ®Google Scholar
• Fowler, D. H. and Gress, R. E. (1997). Graft-versus-host disease as a Th1-type process: regulation by donor cells of Th2 cytokine phenotype. In Graft-vs-host disease, edited by J. L. M. Ferrara, D. H.J., S. J. Burakoff, pp. 479–500. New York. Marcel Dekker, Inc.
   Google Scholar
• Krenger, W. and Ferrara, J. L. M. (1996). Graft-versus-host disease and the Th1/Th2 paradigm. Immunol. Res., 15, 50–73.
   PubMed Web of Science ®Google Scholar
• Storm, T. B., Roy-Chaudhury, P., Manfro, R., Zhen, X. X., Nickerson, P. W. and Wood, K. A. B. (1996) The Th1/Th2 paradigm and the allograft response. Curr. Opin. Immunol., 8, 688–693.
   PubMed Web of Science ®Google Scholar
• Piccotti, J. R., Chan, S. Y. and Goodman, R. E. (1996). IL-12 antagonism induces T helper 2 responses yet exacerbates cardiac allograft rejection. J. Immunol., 157, 1951–1957.
   PubMed Web of Science ®Google Scholar
• Krenger, W., Cooke, K. R., Sonis, S. T., Crawford, J., Simmons, R., Pan, L., Kobzik, L., Delmonte, J., Karandikar, M. and Ferrara, J. L. M. (1996). Transplantation of polarized type 2 donor T cells reduces mortality caused by experimental graft-versus-host disease. Transplantation, 62, 1278–1285.
   PubMed Web of Science ®Google Scholar
• Krenger, W., Snyder, K., Smith, S. and Ferrara, J. L. M. (1994). Effects of exogenous interleukin-10 in a murine model of graft-versus-host disease to minor histocompatibility antigens. Transplantation, 58, 1251–1257.
   PubMed Web of Science ®Google Scholar
• Blazar, B. R., Taylor, P. A., Smith, S. and Vallera, D. A. (1995). Interleukin-10 administration decreases survival in murine recipients of major histocompatibility complex disparate donor bone marrow grafts. Blood., 85, 842–851.
   PubMed Web of Science ®Google Scholar
• Atkinson, K., Matias, C., Guiffre, A., Seymour, R., Cooley, M., BIggs, J., Munro, V. and Gillis, S. (1991) In vivo administration of granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage CSF, interleukin-1 (IL-1), and IL-4, alone and in combination, after allogeneic murine hematopoietic stem cell trasnplantation. Blood., 77, 1376–1382.
   PubMed Web of Science ®Google Scholar
• Bensinger, W. I., Clift, R. A., Anasetti, C., Appelbaum, F. A., Demirer, T., Rowley, S., Sandmaier, B. M., Torok-Storb, B., Storb, R. and Buckner, C. D. (1996). Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony stimulating factor. Stem Cells, 14, 90–105.
   PubMed Web of Science ®Google Scholar
• Pan, L., Delmonte, J., Jalonen, C. K. and Ferrara, J. L. M. (1995). Pretreatment of donors with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type 2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood, 86, 4422–4429.
   PubMed Web of Science ®Google Scholar
• Braun, Y. M., Lowin, B., French, L., Acha-Orbea, H. and Tschopp, J. (1996). Cytotoxic T cells deficient in both functional Fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease. J. Exp. Med., 183, 657–661.
   PubMed Web of Science ®Google Scholar
• Baker, M. B., Altman, N. H., Podack, E. R. and Levy, R. B. (1996). The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice. J. Exp. Med., 183, 2645–2656.
   PubMed Web of Science ®Google Scholar
• Ferrara, J., Gullen, F. J., Sleckman, B., Burakoff, S. J. and Murphy, G. F. (1986). Cutaneous acute graft-versus-host disease to minor histocompatibility antigens in a murine model: Histologic analysis and correlation to clinical disease. J. Invest. Dermatol., 86, 371–375.
   PubMed Web of Science ®Google Scholar
• Hoffman, R. A., Langrehr, J. M. and Simmons, R. L. (1995). Induction of nitric oxide synthesis during the immune response. In Chimerism and Tolerance, edited by S. T. Ildstad, pp. 79–84. R. G. Landes Company.
   Google Scholar
• Graubert, T. A., Russell, J. H. and Ley, T. (1996). The role of granzyme B in murine models of acute graft-versus-host disease and graft rejection. Blood, 87, 1232–1237.
   PubMed Web of Science ®Google Scholar
• Piguet, P. F. (1990). Tumor necrosis factor and graft-versus-host disease. In Graft-vs-Host Disease, edited by Burakoff, S. J., Deeg, H. J., Ferrara, J. L. M. and Atkinson, K. pp. 255–276. New York. Marcel Dekker, Inc.
   Google Scholar
• McCarthy, P. L., Abhyankar, S., Neben, S., Newman, G., Sieff, C., Thompson, R. C., Burakoff, S. J. and Ferrara, J. L. M. (1991). Inhibition of interleukin-1 by an interleukin-1 receptor antagonist prevents graft-versus-host disease. Blood, 78, 1915–1918.
   PubMed Web of Science ®Google Scholar
• Abhyankar, S., Gilliland, D. G. and Ferrara, J. L. M. (1993). Interleukin 1 is a critical effector molecule during cytokine dysregulation in graft-versus-host disease to minor histocompatibility antigens. Transplantation, 56, 1518–1523.
   PubMed Web of Science ®Google Scholar
• Falzarano, G., Krenger, W., Snyder, K. M., Delmonte, J., Karandikar, M. and Ferrara, J. L. M. (1996). Suppression of B cell proliferation to lipopolysaccharide is mediated through induction of the nitric oxide pathway by tumor necrosis factor-α in mice with acute graft-versus-host disease. Blood, 87, 2853–2860.
   PubMed Web of Science ®Google Scholar
• Speiser, D. E., Bachmann, M. F., Frick, T. W., McKall-Faienza, K., Griffiths, E., Pfeffer, K., Mak, T. W. and Ohashi, P. S. (1997). TNF receptor p55 controls early graft-versus-host disease. J. Immunol., 158, 5185–5190.
   PubMed Web of Science ®Google Scholar
• Mollar, B., Ellerman-Eriksen, S., Storgaard, M., Obel, N., Bendtzen, K. and Petersen, C. M. (1996). Soluble tumor necrosis factor (TNF) receptors conserve TNF bioactivity in meningitis patient spinal fluid. J. Infect. Dis., 174, 557–563.
   PubMed Web of Science ®Google Scholar
• Steinshamn, S., Bemelmans, M. H., Buurman, W. A. and Waage, A. (1995). Granulocytopenia reduces release of soluble TNF receptor p75 in endotoxinstimulated mice: a possible mechanism of enhanced TNF activity. Cytokine, 7, 50–60.
   PubMed Web of Science ®Google Scholar